Retinitis Pigmentosa (Retinitis) - Pipeline Review, H2 2015

Date: December 23, 2015
Pages: 161
Price:
US$ 2,000.00 US$ 1,700.00
Offer valid until December 31, 2016!
License [?]:
Publisher: Global Markets Direct
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: R61ADF79FA1EN
Leaflet:

Download PDF Leaflet

Retinitis Pigmentosa (Retinitis) - Pipeline Review, H2 2015

SUMMARY

Global Markets Direct’s, ‘Retinitis Pigmentosa (Retinitis) - Pipeline Review, H2 2015’, provides an overview of the Retinitis Pigmentosa (Retinitis)’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Retinitis Pigmentosa (Retinitis), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Retinitis Pigmentosa (Retinitis) and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

SCOPE
  • The report provides a snapshot of the global therapeutic landscape of Retinitis Pigmentosa (Retinitis)
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for Retinitis Pigmentosa (Retinitis) and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the Retinitis Pigmentosa (Retinitis) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Retinitis Pigmentosa (Retinitis) pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
REASONS TO BUY
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Retinitis Pigmentosa (Retinitis)
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Retinitis Pigmentosa (Retinitis) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Introduction
Global Markets Direct Report Coverage
Retinitis Pigmentosa (Retinitis) Overview
Therapeutics Development
Pipeline Products for Retinitis Pigmentosa (Retinitis) - Overview
Pipeline Products for Retinitis Pigmentosa (Retinitis) - Comparative Analysis
Retinitis Pigmentosa (Retinitis) - Therapeutics under Development by Companies
Retinitis Pigmentosa (Retinitis) - Therapeutics under Investigation by Universities/Institutes
Retinitis Pigmentosa (Retinitis) - Pipeline Products Glance
Late Stage Products
Clinical Stage Products
Early Stage Products
Retinitis Pigmentosa (Retinitis) - Products under Development by Companies
Retinitis Pigmentosa (Retinitis) - Products under Investigation by Universities/Institutes
Retinitis Pigmentosa (Retinitis) - Companies Involved in Therapeutics Development
Acucela Inc.
Amarantus Bioscience Holdings, Inc.
Applied Genetic Technologies Corporation
Asklepios BioPharmaceutical, Inc.
Caladrius Biosciences, Inc.
DNAVEC Corporation
Dompe Farmaceutici S.p.A.
Genable Technologies Limited
Genethon
GenSight Biologics SA
Grupo Ferrer Internacional, S.A.
InFlectis BioScience
International Stem Cell Corporation
Isis Pharmaceuticals, Inc.
Mimetogen Pharmaceuticals Inc.
Neurotech Pharmaceuticals, Inc.
Ocata Therapeutics, Inc.
Orphagen Pharmaceuticals, Inc.
QLT Inc.
RegenxBio Inc.
ReNeuron Group Plc
SanBio, Inc.
Sanofi
Shire Plc
Spark Therapeutics, Inc.
Sucampo Pharmaceuticals, Inc.
Sun Pharma Advanced Research Company Ltd.
Retinitis Pigmentosa (Retinitis) - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
AMRS-001 - Drug Profile
Antibodies to Antagonize IL-6 for Retinitis - Drug Profile
BNP-RP - Drug Profile
CB-11 - Drug Profile
ECL-1 - Drug Profile
emixustat hydrochloride - Drug Profile
FIB-111 - Drug Profile
Gene Therapy for Glaucoma and Retinitis Pigmentosa - Drug Profile
Gene Therapy for Ocular Diseases - Drug Profile
Gene Therapy for Ophthalmology - Drug Profile
Gene Therapy for Retinitis Pigmentosa - Drug Profile
Gene Therapy for Retinitis Pigmentosa - Drug Profile
Gene Therapy to Activate Glutamate Cysteine Ligase and Glutathione Synthase for Retinitis Pigmentosa - Drug Profile
Gene Therapy to Activate HDAC4 for Retinitis Pigmentosa - Drug Profile
Gene Therapy to Activate RPE65 for Leber Congenital Amaurosis - Drug Profile
Gene Therapy to Activate RPGR for X-Linked Retinitis Pigmentosa - Drug Profile
Gene Therapy to Activate RPGR for X-Linked Retinitis Pigmentosa - Drug Profile
GS-030 - Drug Profile
GT-038 - Drug Profile
IFB-088 - Drug Profile
ISIS-RHO2.5Rx - Drug Profile
KIRA-6 - Drug Profile
NT-501 - Drug Profile
OCU-100 - Drug Profile
PRO-015 - Drug Profile
proinsulin human SR - Drug Profile
Recombinant Protein to Agonize p75NTR and Trk for Ophthalmology - Drug Profile
ReN-003 - Drug Profile
Retinal Progenitor Cells for Ophthalmological Disorders - Drug Profile
RGX-321 - Drug Profile
RST-001 - Drug Profile
SAR-421869 - Drug Profile
SB-623 - Drug Profile
SHP-630 - Drug Profile
Small Molecule for Retinitis Pigmentosa - Drug Profile
Small Molecule to Agonize Neurotrophin Receptor for Retinitis Pigmentosa - Drug Profile
Small Molecules for CNS Disorders and Ophthalmology - Drug Profile
Small Molecules for Retinitis Pigmentosa - Drug Profile
Small Molecules for Retinitis Pigmentosa - Drug Profile
Small Molecules to Inhibit Ire1-Alpha for Retinitis Pigmentosa, Type 2 Diabetes and Amyotrophic Lateral Sclerosis - Drug Profile
SPKRPE-65 - Drug Profile
Stem Cell Therapy for Age Related Macular Degeneration and Retinitis Pigmentosa - Drug Profile
Stem Cell Therapy for AMD and Retinitis Pigmentosa - Drug Profile
Stem Cell Therapy for Ophthalmic Disorders - Drug Profile
Stem Cell Therapy to Activate MFRP for Retinitis Pigmentosa - Drug Profile
unoprostone isopropyl - Drug Profile
zuretinol acetate - Drug Profile
Retinitis Pigmentosa (Retinitis) - Recent Pipeline Updates
Retinitis Pigmentosa (Retinitis) - Dormant Projects
Retinitis Pigmentosa (Retinitis) - Discontinued Products
Retinitis Pigmentosa (Retinitis) - Product Development Milestones
Featured News & Press Releases
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

LIST OF TABLES

Number of Products under Development for Retinitis Pigmentosa (Retinitis), H2 2015
Number of Products under Development for Retinitis Pigmentosa (Retinitis) - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Late Stage Development, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Products under Development by Companies, H2 2015
Products under Development by Companies, H2 2015 (Contd..1)
Products under Development by Companies, H2 2015 (Contd..2)
Products under Investigation by Universities/Institutes, H2 2015
Retinitis Pigmentosa (Retinitis) - Pipeline by Acucela Inc., H2 2015
Retinitis Pigmentosa (Retinitis) - Pipeline by Amarantus Bioscience Holdings, Inc., H2 2015
Retinitis Pigmentosa (Retinitis) - Pipeline by Applied Genetic Technologies Corporation, H2 2015
Retinitis Pigmentosa (Retinitis) - Pipeline by Asklepios BioPharmaceutical, Inc., H2 2015
Retinitis Pigmentosa (Retinitis) - Pipeline by Caladrius Biosciences, Inc. , H2 2015
Retinitis Pigmentosa (Retinitis) - Pipeline by DNAVEC Corporation, H2 2015
Retinitis Pigmentosa (Retinitis) - Pipeline by Dompe Farmaceutici S.p.A., H2 2015
Retinitis Pigmentosa (Retinitis) - Pipeline by Genable Technologies Limited, H2 2015
Retinitis Pigmentosa (Retinitis) - Pipeline by Genethon, H2 2015
Retinitis Pigmentosa (Retinitis) - Pipeline by GenSight Biologics SA, H2 2015
Retinitis Pigmentosa (Retinitis) - Pipeline by Grupo Ferrer Internacional, S.A., H2 2015
Retinitis Pigmentosa (Retinitis) - Pipeline by InFlectis BioScience, H2 2015
Retinitis Pigmentosa (Retinitis) - Pipeline by International Stem Cell Corporation, H2 2015
Retinitis Pigmentosa (Retinitis) - Pipeline by Isis Pharmaceuticals, Inc., H2 2015
Retinitis Pigmentosa (Retinitis) - Pipeline by Mimetogen Pharmaceuticals Inc., H2 2015
Retinitis Pigmentosa (Retinitis) - Pipeline by Neurotech Pharmaceuticals, Inc., H2 2015
Retinitis Pigmentosa (Retinitis) - Pipeline by Ocata Therapeutics, Inc., H2 2015
Retinitis Pigmentosa (Retinitis) - Pipeline by Orphagen Pharmaceuticals, Inc., H2 2015
Retinitis Pigmentosa (Retinitis) - Pipeline by QLT Inc., H2 2015
Retinitis Pigmentosa (Retinitis) - Pipeline by RegenxBio Inc., H2 2015
Retinitis Pigmentosa (Retinitis) - Pipeline by ReNeuron Group Plc, H2 2015
Retinitis Pigmentosa (Retinitis) - Pipeline by SanBio, Inc., H2 2015
Retinitis Pigmentosa (Retinitis) - Pipeline by Sanofi, H2 2015
Retinitis Pigmentosa (Retinitis) - Pipeline by Shire Plc, H2 2015
Retinitis Pigmentosa (Retinitis) - Pipeline by Spark Therapeutics, Inc., H2 2015
Retinitis Pigmentosa (Retinitis) - Pipeline by Sucampo Pharmaceuticals, Inc., H2 2015
Retinitis Pigmentosa (Retinitis) - Pipeline by Sun Pharma Advanced Research Company Ltd., H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Retinitis Pigmentosa (Retinitis) Therapeutics - Recent Pipeline Updates, H2 2015
Retinitis Pigmentosa (Retinitis) - Dormant Projects, H2 2015
Retinitis Pigmentosa (Retinitis) - Discontinued Products, H2 2015

LIST OF FIGURES

Number of Products under Development for Retinitis Pigmentosa (Retinitis), H2 2015
Number of Products under Development for Retinitis Pigmentosa (Retinitis) - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Clinical Stage Development, H2 2015
Comparative Analysis by Early Stage Products, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Routes of Administration, H2 2015
Number of Products by Stage and Routes of Administration, H2 2015
Number of Products by Molecule Types, H2 2015
Number of Products by Stage and Molecule Types, H2 2015

COMPANIES MENTIONED

Acucela Inc.
Amarantus Bioscience Holdings, Inc.
Applied Genetic Technologies Corporation
Asklepios BioPharmaceutical, Inc.
Caladrius Biosciences, Inc.
DNAVEC Corporation
Dompe Farmaceutici S.p.A.
Genable Technologies Limited
Genethon
GenSight Biologics SA
Grupo Ferrer Internacional, S.A.
InFlectis BioScience
International Stem Cell Corporation
Isis Pharmaceuticals, Inc.
Mimetogen Pharmaceuticals Inc.
Neurotech Pharmaceuticals, Inc.
Ocata Therapeutics, Inc.
Orphagen Pharmaceuticals, Inc.
QLT Inc.
RegenxBio Inc.
ReNeuron Group Plc
SanBio, Inc.
Sanofi
Shire Plc
Spark Therapeutics, Inc.
Sucampo Pharmaceuticals, Inc.
Sun Pharma Advanced Research Company Ltd.
Skip to top


Ask Your Question

Retinitis Pigmentosa (Retinitis) - Pipeline Review, H2 2015
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: